title: Melatonin can improve insulin resistance and aging-induced pancreas alterations in senescence-accelerated prone male mice (SAMP8).
abstract: The aim of the present study was to investigate the effect of aging on several parameters related to glucose homeostasis and insulin resistance in pancreas and how melatonin administration could affect these parameters. Pancreas samples were obtained from two types of male mice models: senescence-accelerated prone (SAMP8) and senescence-accelerated-resistant mice (SAMR1). Insulin levels in plasma were increased with aging in both SAMP8 and SAMR1 mice, whereas insulin content in pancreas was decreased with aging in SAMP8 and increased in SAMR1 mice. Expressions of glucagon and GLUT2 messenger RNAs (mRNAs) were increased with aging in SAMP8 mice, and no differences were observed in somatostatin and insulin mRNA expressions. Furthermore, aging decreased also the expressions of Pdx-1, FoxO 1, FoxO 3A and Sirt1 in pancreatic SAMP8 samples. Pdx-1 was decreased in SAMR1 mice, but no differences were observed in the rest of parameters on these mice strains. Treatment with melatonin was able to decrease plasma insulin levels and to increase its pancreatic content in SAMP8 mice. In SAMR1, insulin pancreatic content and plasma levels were decreased. HOMA-IR was decreased with melatonin treatment in both strains of animals. On the other hand, in SAMP8 mice, treatment decreased the expression of glucagon, GLUT2, somatostatin and insulin mRNA. Furthermore, it was also able to increase the expression of Sirt1, Pdx-1 and FoxO 3A. According to these results, aging is associated with significant alterations in the relative expression of pancreatic genes associated to glucose metabolism. This has been especially observed in SAMP8 mice. Melatonin administration was able to improve pancreatic function in old SAMP8 mice and to reduce HOMA-IR improving their insulin physiology and glucose metabolism.
authors.affiliation: Department of Physiology, Medical School, University Complutense of Madrid, Madrid, Spain.
authors.forename: Sara
authors.initials: S
authors.lastname: Cuesta
authors.forename: Roman
authors.initials: R
authors.lastname: Kireev
authors.forename: Cruz
authors.initials: C
authors.lastname: García
authors.forename: Lisa
authors.initials: L
authors.lastname: Rancan
authors.forename: Elena
authors.initials: E
authors.lastname: Vara
authors.forename: Jesús A F
authors.initials: JA
authors.lastname: Tresguerres
mesh_terms: D000375:Aging / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D005500:Follow-Up Studies; D018507:Gene Expression Regulation, Developmental; D005934:Glucagon / Q000096:biosynthesis / Q000235:genetics; D051273:Glucose Transporter Type 2 / Q000096:biosynthesis / Q000235:genetics; D007328:Insulin / Q000235:genetics / Q000378:metabolism; D007333:Insulin Resistance / Q000502:physiology*; D008297:Male; D008550:Melatonin / Q000494:pharmacology*; D051379:Mice; D018384:Oxidative Stress / Q000187:drug effects / Q000502:physiology*; D010179:Pancreas / Q000187:drug effects / Q000378:metabolism*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D060888:Real-Time Polymerase Chain Reaction
chemical_list: D000975:Antioxidants; D051273:Glucose Transporter Type 2; D007328:Insulin; D012333:RNA, Messenger; C495682:Slc2a2 protein, mouse; D005934:Glucagon; D008550:Melatonin